Ken Herrmann Sells 4,856 Shares of Aktis Oncology (NASDAQ:AKTS) Stock

Aktis Oncology (NASDAQ:AKTS) Director Ken Herrmann sold 4,856 shares of Aktis Oncology stock in a transaction on Monday, July 20th. The shares were sold at an average price of $24.56, for a total transaction of $119,263.36. Following the completion of the transaction, the director directly owned 3,506 shares of the company’s stock, valued at $86,107.36. The trade was a 58.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Aktis Oncology Stock Performance

Shares of Aktis Oncology stock opened at $22.39 on Thursday. The firm has a 50-day simple moving average of $24.14 and a two-hundred day simple moving average of $20.92. Aktis Oncology has a fifty-two week low of $14.72 and a fifty-two week high of $34.19. The company has a market cap of $1.20 billion and a P/E ratio of -58.92.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings results on Monday, May 11th. The technology company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). The company had revenue of $3.23 million during the quarter, compared to analysts’ expectations of $2.23 million. Equities research analysts forecast that Aktis Oncology will post -1.64 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on AKTS shares. Weiss Ratings raised shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. JPMorgan Chase & Co. increased their price objective on shares of Aktis Oncology from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Tuesday, July 14th. Raymond James Financial initiated coverage on shares of Aktis Oncology in a research report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 target price on the stock. HC Wainwright upped their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Finally, William Blair initiated coverage on shares of Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.60.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.